2.655

8.85% 0.205

Rocket Pharmaceuticals Inc (RCKT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.45

Offen:

$2.43

24-Stunden-Volumen:

2.44M

Relative Volume:

0.52

Marktkapitalisierung:

$340.45M

Einnahmen:

Nettoeinkommen (Verlust:

$-258.08M

KGV:

-0.9655

EPS:

-2.75

Netto-Cashflow:

$-202.32M

1W Leistung:

-3.72%

1M Leistung:

+6.25%

6M Leistung:

-78.78%

1J Leistung:

-87.09%

1-Tages-Spanne:

$2.40

$2.715

1-Wochen-Bereich:

$2.40

$2.7953

52-Wochen-Spanne:

$2.19

$26.98

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Firmenname

Rocket Pharmaceuticals Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (661)

Telefon

646-440-9100

Adresse

350 FIFTH AVENUE, NEW YORK, NY

Mitarbeiter

299

Twitter

@rocketpharma

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

RCKT's Discussions on Twitter

Vergleichen Sie RCKT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RCKT Rocket Pharmaceuticals Inc	2.665	340.45M	0	-258.08M	-202.32M	-2.75
VRTX Vertex Pharmaceuticals Inc	452.69	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	541.99	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	323.44	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	550.66	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.78	28.51B	3.81B	-644.79M	-669.77M	-6.24

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-30	Herabstufung	Evercore ISI	Outperform → In-line
2025-05-28	Herabstufung	Goldman	Neutral → Sell
2025-05-28	Herabstufung	JP Morgan	Overweight → Neutral
2025-05-28	Herabstufung	Jefferies	Buy → Hold
2025-05-28	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-05-28	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-05-27	Herabstufung	Needham	Buy → Hold
2025-05-27	Herabstufung	TD Cowen	Buy → Hold
2025-03-12	Eingeleitet	BMO Capital Markets	Outperform
2024-12-30	Eingeleitet	Wedbush	Outperform
2024-12-18	Eingeleitet	Jefferies	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-04-02	Eingeleitet	Goldman	Neutral
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-02-01	Eingeleitet	Morgan Stanley	Overweight
2022-11-08	Eingeleitet	Canaccord Genuity	Buy
2022-11-01	Eingeleitet	BTIG Research	Buy
2022-07-08	Eingeleitet	Raymond James	Outperform
2021-10-20	Fortgesetzt	Cowen	Outperform
2021-03-02	Eingeleitet	Stifel	Buy
2021-02-18	Eingeleitet	Needham	Buy
2020-12-16	Eingeleitet	UBS	Buy
2020-12-08	Herabstufung	Oppenheimer	Outperform → Perform
2020-07-02	Eingeleitet	JP Morgan	Overweight
2020-06-25	Fortgesetzt	BofA/Merrill	Buy
2020-06-01	Fortgesetzt	Oppenheimer	Outperform
2019-11-06	Eingeleitet	Chardan Capital Markets	Buy
2019-09-26	Eingeleitet	Piper Jaffray	Overweight
2019-04-23	Eingeleitet	Robert W. Baird	Outperform
2019-03-15	Eingeleitet	BofA/Merrill	Buy
2019-02-05	Eingeleitet	Oppenheimer	Outperform
2018-09-13	Eingeleitet	Ladenburg Thalmann	Buy
2018-07-10	Eingeleitet	William Blair	Outperform

Alle ansehen

Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten

Jun 18, 2025

Investors who lost money with shares of Rocket Pharmaceuticals, - openPR.com

Jun 18, 2025

Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Benzinga

Jun 18, 2025

Rocket Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 18, 2025

RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

Jun 18, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent

Jun 18, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $5.00 at UBS Group - Defense World

Jun 18, 2025

Jun 17, 2025

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire

Jun 17, 2025

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Analyst | - GuruFocus

Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire

Jun 17, 2025

UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating - MarketScreener

Jun 17, 2025

UBS Adjusts Price Target for Rocket Pharmaceuticals (RCKT) Amid Program Developments | RCKT Stock News - GuruFocus

Jun 17, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. LawsuitRCKT - PR Newswire

Jun 17, 2025

Jun 16, 2025

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire

Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph

Jun 16, 2025

Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - GuruFocus

Jun 16, 2025

Jun 15, 2025

Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - ACCESS Newswire

Jun 15, 2025

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - ACCESS Newswire

Jun 15, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - marketscreener.com

Jun 15, 2025

RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 15, 2025

RCKT Investor Notice: Robbins LLP Reminds Shareholders of - GlobeNewswire

Jun 15, 2025

Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead By Investing.com - Investing.com South Africa

Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead - Investing.com Australia

Jun 14, 2025

RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire

Jun 14, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jun 13, 2025

ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView

Jun 13, 2025

RCKT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 13, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - ACCESS Newswire

Jun 13, 2025

Contact Levi & Korsinsky by August 11, 2025 Deadline to - GlobeNewswire

Jun 13, 2025

RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Business Wire

Jun 13, 2025